Neethu Sreenivasan

Biopharma consultant. Interest topics - Biosimilars, oncology & immunology. Posts/tweets here are personal and DO NOT reflect/represent the views of my employer

[Simons @Simon_Ingari]

Employees who experience mental burnout at work :

MONDAY - 100%
TUESDAY - 100%
WEDNESDAY - 100%
THURSDAY - 100%
FRIDAY - 100%

Employees who rarely experience mental burnout at work:

[Course5 Life Sciences @Course5_LifeSci]

#Hola from #barcelona. At @RE_Pharma Helping customers drive decisions across value chain using #ArtificialIntelligence & #analytics. Improving #marketingstrategy & driving #omnichannel
#repharma2023 #GenerativeAI #pharma #PatientCare #DataAnalytics @Course5_LifeSci @Course5i

[Course5 Life Sciences @Course5_LifeSci]

#AACR23 is just around the corner!
From the multiple data sessions, Course5i selected a few data that will showcase clinical and preclinical results of promising new IO targets and emerging modalities in cancer research. #solidtumors #oncology #immunotherapy #CancerResearch

[Neethu Sreenivasan @neeth_sa]

@bradloncar Gilead and Arcus' ARC7 - a hype or hope? The glimpse of the PFS curves would be the most awaited on Dec 20th!

[Course5 Life Sciences @Course5_LifeSci]

#SITC22 Updates: $ABBV’s ABBV-151 (GARP-TGF-β1 mAb) + budigalimab (PD-1) showed ORR 16% & 8% in the PD-1 R/R UC & PD-1 naive MSS-CRC expansion cohorts resp.; manageable safety profile – Positive data to support Ph2 plans in these indications
#CRC #immunooncology #CancerResearch

[Course5 Life Sciences @Course5_LifeSci]

#SITC22 Updates: Remarkable ORR of 69% (9/13 pts) for Oncolytic Biotech's #pelareorep (oncolytic reovirus) +atezolizumab+chemo in pancreatic cancer, >2x rate vs ~25% for historical controls – warrants further evaluation in this setting
#PancreaticCancer #oncology #CancerResearch

[Juan P. Serrate, DVM @JPZaragoza1]

Will this jump in the $XBI be short lived? Maybe a good time to short it before next readouts at CTAD

[Neethu Sreenivasan @neeth_sa]

An insightful exchange between @bradloncar and @JacobPlieth on what to expect for #ESMO22 - movers and shakers

[Brad Loncar @bradloncar]

https://t.co/uLD0ngDfUd

[Guillermo Garcia-Manero @garciamanero]

Dr Bose ready to talk on myelofibrosis at the Zeev Estrov Leukemia Research Meeting at MD Anderson. ⁦@MDAndersonNews⁩ ⁦@Lisa_Palacios⁩

[Course5 Life Sciences @Course5_LifeSci]

$AZN (#AstraZeneca) Q2 results
Early-stage #oncology pipeline- Adavosertib (WEE1 inhibitor) in Ph2 removed due to safety concerns
#Zentalis’ Zn-c3 leads among #WEE1 inhibitors in solid #tumors with pivotal trials -> FDA discussion ongoing
https://t.co/pQO4LJOImc

[Prithviraj Bose @bose_prithviraj]

Great to see the much awaited MOMENTUM data masterfully presented by @mpdrc at #ASCO22. Key points: min TSS 10, max Hgb 10 at baseline, median prior JAKi 2+ y. 130 MMB (200 mg/d), 65 DAN (600 mg/d). Week 24 TSS50 25% vs. 9%, SVR35 23% vs. 3%, TI 31% vs. 20%. PN 4% vs. 2%. #mpnsm

[Brad Loncar @bradloncar]

My only two #ASCO22 predictions this weekend (and admittedly these aren't going out on a limb).

1. Enhertu will be ASCO22's biggest news.
2. Tropics-02 will be so bad (< 1 month PFS).

I'm intrigued to see the adicet gamma delta update. Also, a big moment for CD3 bi-specifics.

[Brad Loncar @bradloncar]

On Wednesday, #ASCO22 Abstract Titles, including LBAs, are posted. Titles only though.

[Neethu Sreenivasan @neeth_sa]

@EMA_News Isn't this a Cell / CAR-T therapy? The announcement title says gene therapy..

[Neethu Sreenivasan @neeth_sa]

@MD_Doc_USA Have there been any shortages of ESAs for clinical use?

[SellDrugs @SellDrugs_]

Pharma roles explained…
https://t.co/8O4sTiyfFj

[Neethu Sreenivasan @neeth_sa]

@Dr_AmerZeidan @CCO_Education Great talks! Thank you! Missed seeing the panel online.. guess that was a perk only for those who were live at Marriot Marquis.

[Neethu Sreenivasan @neeth_sa]

@VincentRK @SagarLonialMD @Rfonsi1 @IreneGhobrial @myelomaMD @szusmani @chadinabhan @mvmateos @ASH_hematology how do we join in ?

[Neethu Sreenivasan @neeth_sa]

Next destination! Peppa Pig World.. My kind of place.. CBI conference say Sieze the moment! Here's how you do it

[BBC Politics @BBCPolitics]

"Yesterday I went to Peppa Pig World... I loved it, it's very much my kind of place"

PM Boris Johnson tells CBI conference "no Whitehall civil servant would conceivably come up with Peppa" as he praises the "power of UK creativity"

https://t.co/jtIu0zy7g3

[Neethu Sreenivasan @neeth_sa]

@DrManuelThomas1 Hello Manuel Sir! Nice to see you around here! Hope all is well